A major challenge faced by the gene‑modified T cell therapy industry is cell expansion and editing using conventional methods. Equally, while NK cells represent an attractive option for an “off the shelf” cell therapy, there are challenges that must be overcome in working with them too.

In this webinar, we discuss tools and protocols for T and NK cell therapy workflows, and review data that show efficient gene editing and post‑electroporation viability for both T cells and NK cells.

• Discuss the potential of human NK cells grown in feeder free medium in a clinical setting
• We present non‑viral, gene‑specific integration and innovative cell processing and expansion technologies that clinicians can leverage in development workflows and clinical manufacturing
• Review how to transition from the small benchtop Invitrogen Neon system to the large‑scale CTS Xenon system, suitable for clinical manufacturing